Pneumonia developing ≥48 h after hospital admission or ≥48 h after intubation.
Also known as: HAP, VAP, nosocomial pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia
Overview
HAP: pneumonia occurring ≥48 hours after hospital admission not incubating at admission. VAP: pneumonia developing ≥48 hours after endotracheal intubation. Caused by hospital-flora organisms with frequent multidrug resistance.
Epidemiology
HAP is the second most common nosocomial infection. VAP develops in 10-20% of patients ventilated >48 h, with attributable mortality up to 13%. Resistant pathogens (MRSA, Pseudomonas, Acinetobacter, ESBL Enterobacterales) increasingly common.
Try two board-style Hospital-Acquired and Ventilator-Associated Pneumonia questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1PulmonaryMedium
A 60-year-old man in the ICU develops fever to 38.9 C, leukocytosis, increasing purulent tracheal secretions, and a new right lower lobe infiltrate on chest radiograph 3 days after intubation for respiratory failure. He has no known multidrug-resistant organism risk factors. Empiric therapy is initiated before culture results return. Which of the following antibiotics is most appropriate?
ATrimethoprim-sulfamethoxazole
BPiperacillin-tazobactam
CErtapenem
DCeftriaxone
EAzithromycin
Reveal answer & full explanation
Correct answer: B — Piperacillin-tazobactam
ATrimethoprim-sulfamethoxazole
BPiperacillin-tazobactam✓
CErtapenem
DCeftriaxone
EAzithromycin
Why Piperacillin-tazobactam is correct
This is ventilator-associated pneumonia (VAP), defined as a new infiltrate with systemic signs of infection arising 48 hours or more after intubation.
VAP is frequently caused by drug-resistant gram-negative organisms, most notably Pseudomonas aeruginosa, as well as MRSA and Acinetobacter, so empiric coverage must include an anti-pseudomonal agent.
Piperacillin-tazobactam is an anti-pseudomonal beta-lactam and is an appropriate empiric backbone; cefepime or meropenem are alternatives.
Because piperacillin-tazobactam does not cover MRSA, empiric vancomycin or linezolid is typically added unless local MRSA prevalence is documented low, with de-escalation once cultures return.
Why the others are wrong
Ceftriaxone — Ceftriaxone is a third-generation cephalosporin appropriate for community-acquired pneumonia but lacks reliable anti-pseudomonal activity, making it inadequate for VAP.
Trimethoprim-sulfamethoxazole — Trimethoprim-sulfamethoxazole is used for Stenotrophomonas, Pneumocystis, and some MRSA infections but does not cover Pseudomonas empirically.
Azithromycin — Azithromycin targets atypical pathogens such as Legionella and Mycoplasma in community-acquired pneumonia and has no role as empiric monotherapy for ventilator-associated pneumonia.
Ertapenem — a carbapenem, so it looks broad, and older early-onset VAP schemes allowed it, but unlike meropenem it lacks activity against Pseudomonas aeruginosa and Acinetobacter, and current IDSA/ATS guidance calls for antipseudomonal coverage in every empiric VAP regimen, even without MDR risk factors; a wrong-carbapenem trap.
Question 2Infectious DiseaseMedium
A 68-year-old male with COPD develops fever, productive cough, and new right lower lobe consolidation on hospital day 6 of an admission for a COPD exacerbation. WBC is 22K. No methicillin-resistant Staphylococcus aureus (MRSA) or Pseudomonas risk factors are identified. Which of the following empiric antibiotic regimens is most appropriate?
AAmoxicillin-clavulanate
BPiperacillin-tazobactam
CIntravenous ertapenem
DCeftriaxone plus azithromycin
EIntravenous moxifloxacin
Reveal answer & full explanation
Correct answer: B — Piperacillin-tazobactam
AAmoxicillin-clavulanate
BPiperacillin-tazobactam✓
CIntravenous ertapenem
DCeftriaxone plus azithromycin
EIntravenous moxifloxacin
Why Piperacillin-tazobactam is correct
New consolidation arising on hospital day 6 (onset >48 hours after admission) defines hospital-acquired pneumonia (HAP)
Per the 2016 IDSA/ATS HAP/VAP guideline, empiric therapy must cover gram-negative pathogens including Pseudomonas aeruginosa, so a single anti-pseudomonal beta-lactam is appropriate when MRSA and double-Pseudomonas-coverage criteria are not met
Piperacillin-tazobactam, cefepime, imipenem, and meropenem are the guideline's anti-pseudomonal beta-lactam options for this low-risk HAP scenario
Why the others are wrong
Amoxicillin-clavulanate — lacks the anti-pseudomonal activity required for HAP empiric therapy (right-setting-wrong-spectrum)
Ceftriaxone plus azithromycin — a community-acquired pneumonia regimen that does not cover Pseudomonas aeruginosa and is inappropriate for nosocomial-onset disease (confused-with CAP)
Intravenous ertapenem — unlike imipenem and meropenem, ertapenem lacks reliable activity against Pseudomonas aeruginosa, and empiric HAP coverage must include Pseudomonas even when risk factors for resistant organisms are absent, so it is not among the guideline's empiric options (right-class-wrong-spectrum)
Intravenous moxifloxacin — a respiratory fluoroquinolone with strong activity against typical and atypical community-acquired pneumonia pathogens, but unlike levofloxacin and ciprofloxacin it lacks reliable activity against Pseudomonas aeruginosa, so it does not provide the anti-pseudomonal coverage that empiric HAP therapy requires (right-class-wrong-agent)
Additional high-yield points
Most HAP is treated for 7 days, with de-escalation guided by culture data
Procalcitonin trends can help shorten antibiotic duration
The obsolete HCAP category is no longer used; prior hospitalization alone does not define HAP
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Recent influenza or other respiratory viral infection
Pathophysiology
Aspiration of oropharyngeal secretions colonized with hospital flora past an endotracheal tube cuff. Biofilm on the ETT serves as a reservoir. Common pathogens: Pseudomonas aeruginosa, Staphylococcus aureus (including MRSA), Klebsiella, E. coli, Enterobacter, Acinetobacter, Stenotrophomonas. Anaerobes are LESS important than previously thought.
Clinical presentation
Symptoms
New or worsening dyspnea, purulent tracheobronchial secretions
Fever, chills
Mental status change (especially in elderly)
Often subtle in ventilated/sedated patients — recognize by changes in vent parameters
Signs / physical exam
New fever or hypothermia, leukocytosis or leukopenia
Hypoxia, increasing FiO2 or PEEP requirements
Purulent endotracheal aspirate
New crackles or focal lung findings
Differential diagnosis
Atelectasis — Post-op or immobilized; rapid resolution with recruitment; no leukocytosis or fever pattern
Tracheobronchitis without pneumonia — Purulent secretions without new infiltrate; signs and inflammatory markers less pronounced
Diagnostic workup
Diagnostic criteria
Clinical: new or progressive radiographic infiltrate + ≥2 of (fever >38°C, leukocytosis/leukopenia, purulent secretions, hypoxemia, increasing ventilator support). Microbiologic confirmation strongly preferred to guide therapy.
Labs
CBC, BMP, lactate, blood cultures × 2
Lower respiratory tract sampling BEFORE antibiotic change: endotracheal aspirate with semiquantitative culture is preferred (ATS/IDSA 2016); BAL, mini-BAL, or protected brush with quantitative culture is an alternative (diagnostic thresholds ≥10⁴ CFU/mL BAL, ≥10³ CFU/mL protected brush)
Multiplex PCR panels for rapid pathogen identification
Procalcitonin trend can guide de-escalation/duration
Imaging
CXR — new or progressive infiltrate (essential for diagnosis)
CT chest if complicated (cavitation, empyema, abscess) or radiograph indeterminate
Diagnostic algorithm
Risk Tier
Empiric Coverage
HAP, not high mortality risk and no MRSA risk factors
One antipseudomonal agent with MSSA activity (e.g., piperacillin-tazobactam, cefepime, levofloxacin, or a carbapenem)
HAP with MRSA risk only (unit MRSA >20% or unknown), not high mortality risk
One antipseudomonal agent + vancomycin or linezolid
HAP with high mortality risk (ventilatory support for HAP or septic shock) or IV antibiotics within 90 days
Two antipseudomonal agents from different classes (not two beta-lactams) + vancomycin or linezolid
VAP
Antipseudomonal agent (usually a beta-lactam); add vancomycin or linezolid if MDR risk factors, unit MRSA >10-20%, or rate unknown; add a second antipseudomonal from a different class if MDR risk factors, >10% of gram-negatives resistant to the monotherapy agent, or local susceptibility unknown
Known prior MDR pathogen
Tailor to prior isolate and antibiogram
ATS/IDSA 2016 empiric antibiotic stratification for HAP and VAP.
Treatment
First-line
Empiric therapy targets MRSA and Pseudomonas in most VAP and in HAP with risk factors
Antipseudomonal beta-lactam: piperacillin-tazobactam 4.5 g IV q6h (extended infusion), cefepime 2 g IV q8h, ceftazidime 2 g IV q8h, meropenem 1 g IV q8h, imipenem
MRSA coverage: vancomycin (AUC-guided dosing, target AUC 400-600 mg·h/L; trough-only targeting of 15-20 mg/L is no longer recommended) OR linezolid 600 mg IV q12h
Add second antipseudomonal (aminoglycoside — amikacin/gentamicin/tobramycin — or fluoroquinolone — ciprofloxacin/levofloxacin) ONLY if MDR risk factors, high mortality risk (HAP with septic shock or need for ventilatory support), or in VAP >10% of local gram-negative isolates resistant to the monotherapy agent or unknown local susceptibility; never two beta-lactams. MDR risk factors for VAP: IV antibiotics within 90 days, septic shock at onset, ARDS before VAP, ≥5 days of hospitalization before onset, acute renal replacement therapy; for HAP: IV antibiotics within 90 days (also the MRSA and Pseudomonas risk factor)
Tailor based on local antibiogram and prior cultures within 90 days
Second-line / adjunct
De-escalate to narrowest agent once culture and sensitivities return; stop MRSA coverage if MRSA not isolated
Duration: 7 days for most HAP/VAP (ATS/IDSA 2016) — even with non-fermenting GNRs like Pseudomonas, provided clinical response
Adjuncts to prevent VAP: head of bed 30-45°, daily sedation interruptions and spontaneous breathing trials, oral care with toothbrushing (oral chlorhexidine is no longer recommended; possible increased mortality), subglottic suction ETTs, early mobilization, stress ulcer prophylaxis only when indicated
Empyema, lung abscess, necrotizing pneumonia (especially S. aureus, Klebsiella)
Antibiotic-associated complications: C. difficile, AKI, antimicrobial resistance
Death — attributable mortality ~13% for VAP
PANCE pearls
HCAP (healthcare-associated pneumonia) was eliminated from ATS/IDSA guidelines in 2016 — it overestimated resistance and led to overtreatment.
ATS/IDSA 2016 prefers noninvasive endotracheal aspirate with semiquantitative culture; invasive quantitative sampling (BAL) did not improve mortality or ventilator days, but a result below threshold supports withholding or stopping antibiotics.
A 7-day course is appropriate for most HAP/VAP, including non-fermenters such as Pseudomonas, provided clinical response (ATS/IDSA 2016); in the PneumA trial (8 vs 15 days) mortality was equal, but non-fermenter VAP recurred more often with the shorter course.
Procalcitonin algorithms can shorten antibiotic duration without worsening outcomes (SAPS trial).
Stenotrophomonas maltophilia — resistant to most beta-lactams and carbapenems; first-line is TMP-SMX.
References
ATS/IDSA 2016 — Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia (Kalil et al., Clin Infect Dis 2016)
PneumA Trial — Comparison of 8 vs 15 Days of Antibiotic Therapy for VAP (Chastre et al., JAMA 2003)
SAPS Trial — Efficacy and Safety of Procalcitonin Guidance in Reducing Duration of Antibiotic Treatment in Critically Ill Patients (de Jong et al., Lancet Infect Dis 2016)
SHEA/IDSA 2022 — Strategies to Prevent Ventilator-Associated Pneumonia, Ventilator-Associated Events, and Nonventilator Hospital-Acquired Pneumonia (Klompas et al., Infect Control Hosp Epidemiol 2022)
ASHP/IDSA/PIDS/SIDP 2020 — Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review (Rybak et al., Am J Health-Syst Pharm 2020)
Practice Pulmonary questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.